Beovu lawsuits are being filed by people who received at least one Beovu injection and have since been diagnosed with:
Beovu was approved by the FDA for treatment of wet age-related macular degeneration (AMD) in October 2019. By February 2020, 14 patients who had been injected with Beovu had developed retinal inflammation (vasculitis) according to the American Society of Retina Specialists (ASRS), prompting the ASRS to issue a warning to its members about the drug. Eleven of those 14 patients were also diagnosed with occlusive retinal vasculitis, an inflammatory eye condition that can lead to blindness. Just one month later, there were 25 reported cases of retinal vasculitis in patients who had been treated with Beovu, and 21 of those involved retinal occlusion.
The Beovu lawsuits claim the manufacturer did not warn doctors and patients about these potentially severe, vision-limiting side effects associated with Beovu.
Trustwell Law is accepting Beovu lawsuits. If you or a loved one received at least one Beovu injection and have been diagnosed with blindness, retinal vasculitis, retinal artery occlusion, occlusive retinal vasculitis, intraocular inflammation, or documented vision loss, you may be entitled to compensation.
At Trustwell Law, our experienced attorneys take a personalized, compassionate approach. We cut through the legalese and partner with our clients. We also have access to the expertise, resources, and manpower to fully investigate each case and fight for and with our clients to get the justice they deserve.
If you are considering filing a Beovu lawsuit, call us at 800-796-1636 or submit your case details online and someone will contact you shortly. You pay nothing unless your lawsuit is successful and you receive compensation.
There are two kinds of macular degeneration—wet and dry. Only 10 to 15 percent of macular degeneration cases are the wet type.
Wet macular degeneration develops when abnormal blood vessels grow under the retina and macula of the eye. If and when these blood vessels bleed and leak fluid, it causes the macula to bulge—raising it up from its normal flat position and distorting or destroying the person’s central vision.
Wet AMD symptoms often appear suddenly and may worsen rapidly. Wet macular degeneration symptoms may include:
AMD does not affect peripheral (side) vision, so it rarely leads to blindness.
Beovu (brolucizumab), manufactured by Novartis, is a treatment for wet AMD. Beovu is administered by a shot into the eye (called an intravitreal injection) to suppress the growth of abnormal blood vessels and thereby minimize leakage and resulting scar tissue that interferes with central vision.
Beovu was first approved by the FDA for the treatment of wet age-related macular degeneration in October 2019. The original package insert listed several potential side effects, including blurred vision, cataracts, eye hemorrhage, and blood vessel inflammation in the back of the eye.
However, by early 2020, health practitioners had noticed other side effects and the American Society of Retina Specialists issued its warning to its members about the drug.
In June 2020, the FDA approved an update to the Beovu label that included the following warning: “Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported following BEOVU…Patients should be instructed to report any change in vision without delay.”
The National Library of Medicine reports several potential side effects associated with Beovu injections that can lead to serious complications and may be precursors to or indicative of retinal vasculitis or retinal artery occlusion. They are:
They warn that anyone experiencing one or more of these side effects after receiving a Beovu injection should contact their doctor immediately.
Vasculitis is inflammation of blood vessels. Blood vessel walls can thicken when inflamed, becoming weaker or narrower and scarred, which restricts blood flow.
In cases of retinal vasculitis, the blood vessels involved are in the retina, the thin layer of tissue lining the back of the eye which is the part of the eye that senses light and allows us to see. The inflammation of the blood vessels damages the eye.
Inflammation of the retinal-based blood vessels can also lead to occlusion, meaning that the blood flow to the eye is blocked or limited. Retinal vasculitis and retinal artery occlusion can lead to blindness.
If you or a loved one received Beovu injection(s) and have been diagnosed with retinal vasculitis, retinal artery occlusion, occlusive retinal vasculitis, intraocular inflammation, vision loss, or blindness, you may be entitled to compensation. Contact us for a free consultation by calling 800-796-1636 . Or submit your case details online, and someone will contact you shortly.
American Academy of Ophthalmology. (2019, December 16). Retinal vasculitis. Retrieved from https://eyewiki.aao.org/Retinal_Vasculitis#Symptoms
American Macular Degeneration Foundation. (n.d.). Wet Macular Degeneration. Retrieved from https://www.macular.org/wet-amd
Cleveland Clinic. (n.d.). Retinal vein occlusion. Retrieved from https://my.clevelandclinic.org/health/diseases/14206-retinal-vein-occlusion-rvo
Kondapalli, S.S.A. (2020, August 6). Retinal Vasculitis After Administration of Brolucizumab Resulting in Severe Loss of Visual Acuity. Retrieved from https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2768911
Linneham, R. (2020, February 25). Novartis responds to ASRS update on safety of Beovu. Retrieved from https://www.healio.com/news/ophthalmology/20200225/novartis-responds-to-asrs-update-on-safety-of-beovu
Mayo Clinic. (2020, November 24). Vasculitis. Retrieved from https://www.mayoclinic.org/diseases-conditions/vasculitis/symptoms-causes/syc-203634350
Mayo Clinic. (2020, December 11). Wet macular degeneration. Retrieved from https://www.mayoclinic.org/diseases-conditions/wet-macular-degeneration/diagnosis-treatment/drc-20351113
Novartis. (2020, April 8). Novartis completes safety review and initiates update to the Beovu prescribing information worldwide. Retrieved from https://www.novartis.com/news/novartis-completes-safety-review-and-initiates-update-beovu-prescribing-information-worldwide
Novartis. (2020, June 11). US FDA approves updated Novartis Beovu label, to include additional safety information. Retrieved from https://www.novartis.com/news/media-releases/us-fda-approves-updated-novartis-beovu-label-include-additional-safety-information
Sagonowsky, E. (2020, March 4). ‘Lightning struck’: How a safety alert shifted doctor sentiment on Novartis’ Beovu. Retrieved from https://www.fiercepharma.com/pharma/lightning-struck-how-a-safety-alert-shifted-doctor-sentiment-novartis-beovu
Sridhar, J. (2020, June 11). FDA to update Beovu label to include additional safety information. Retrieved from https://www.healio.com/news/ophthalmology/20200702/fda-to-update-beovu-label-to-include-additional-safety-information#top
U.S. National Library of Medicine. (2020, January 15). Brolucizumab-dbll Injection. Retrieved from https://medlineplus.gov/druginfo/meds/a620001.html